| P50 | author | Maria Luisa Brandi | Q29839820 |
| P2093 | author name string | Cecilia Romagnoli | |
| | Federica D'Asta | |
| P2860 | cites work | Bone morphogenic protein-2 (BMP-2) loaded hybrid coating on porous hydroxyapatite scaffolds for bone tissue engineering | Q85944877 |
| | Comparison of anterior and posterior iliac crest bone grafts in terms of harvest-site morbidity and functional outcomes | Q28217135 |
| | Complications of iliac crest bone graft harvesting | Q28287579 |
| | Iliac crest bone graft harvest donor site morbidity. A statistical evaluation | Q28295065 |
| | The promise of chitosan microspheres in drug delivery systems | Q31112020 |
| | Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds | Q33742858 |
| | Bone graft materials. An overview of the basic science. | Q33849619 |
| | Bone regeneration: current concepts and future directions | Q33917394 |
| | Polysaccharide colloidal particles as delivery systems for macromolecules | Q34184373 |
| | Morbidity at bone graft donor sites | Q34549541 |
| | Bone-grafting and bone-graft substitutes. | Q34557248 |
| | The role of growth factors in the repair of bone. Biology and clinical applications. | Q34683755 |
| | Bone morphogenetic proteins, their antagonists, and the skeleton | Q35109618 |
| | Chitosan microspheres as a potential carrier for drugs | Q35741495 |
| | Localized delivery of growth factors for bone repair. | Q35857054 |
| | BMP signaling in skeletal development | Q36032053 |
| | Delivery of bone morphogenetic proteins for orthopedic tissue regeneration | Q36152456 |
| | Calcium phosphate ceramic systems in growth factor and drug delivery for bone tissue engineering: a review | Q36160994 |
| | Recent advances in bone tissue engineering scaffolds. | Q36252678 |
| | Bone substitutes: an update | Q36269863 |
| | Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering. | Q36407629 |
| | Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion | Q36409911 |
| | Collagen-hydroxyapatite composites for hard tissue repair. | Q36433773 |
| | Biodegradable polymeric scaffolds. Improvements in bone tissue engineering through controlled drug delivery | Q36647064 |
| | Growth factors in bone | Q36748632 |
| | Bioactive scaffolds for bone and ligament tissue. | Q36815193 |
| | Polymer carriers for drug delivery in tissue engineering | Q36836333 |
| | Mesoporous materials for drug delivery. | Q36939951 |
| | Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering. | Q36961185 |
| | Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). | Q37126334 |
| | A clinically relevant model of osteoinduction: a process requiring calcium phosphate and BMP/Wnt signalling | Q37311061 |
| | Macroporous scaffolds associated with cells to construct a hybrid biomaterial for bone tissue engineering | Q37331741 |
| | Complications of recombinant human BMP-2 for treating complex tibial plateau fractures: a preliminary report | Q37411094 |
| | Recent advances in ceramic implants as drug delivery systems for biomedical applications | Q37428805 |
| | Bone tissue engineering: a review in bone biomimetics and drug delivery strategies. | Q37613571 |
| | Bone morphogenetic proteins in orthopaedic trauma surgery | Q37818815 |
| | What should be the characteristics of the ideal bone graft substitute? Combining scaffolds with growth factors and/or stem cells | Q37896986 |
| | Mesoporous bioactive glasses as drug delivery and bone tissue regeneration platforms | Q38029622 |
| | Formulations and delivery vehicles for bone morphogenetic proteins: latest advances and future directions | Q39905847 |
| | Insulin-like growth factor I-releasing alginate-tricalciumphosphate composites for bone regeneration | Q40411392 |
| | Prolonged ectopic calcification induced by BMP-2-derived synthetic peptide. | Q40549773 |
| | Physical and monetary costs associated with autogenous bone graft harvesting. | Q40605789 |
| | Common principles in cell adhesion | Q41112042 |
| | Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB. | Q42026394 |
| | A bioactive coating of a silica xerogel/chitosan hybrid on titanium by a room temperature sol-gel process | Q42798132 |
| | Silica-chitosan hybrid coating on Ti for controlled release of growth factors | Q42804245 |
| | RGD-conjugated copolymer incorporated into composite of poly(lactide-co-glycotide) and poly(L-lactide)-grafted nanohydroxyapatite for bone tissue engineering | Q42810410 |
| | Biomimicry in biomedical research | Q43129248 |
| | In vivo osteogenic response to different ratios of BMP-2 and VEGF released from a biodegradable porous system | Q43438576 |
| | Poly(L-lysine)-GRGDS as a biomimetic surface modifier for poly(lactic acid). | Q43541313 |
| | Repair of rabbit femoral defects with a novel BMP2-derived oligopeptide P24. | Q43611175 |
| | Development and in vitro characterisation of novel bioresorbable and bioactive composite materials based on polylactide foams and Bioglass for tissue engineering applications | Q44091086 |
| | Hierarchical mesoporous bioactive glass/alginate composite scaffolds fabricated by three-dimensional plotting for bone tissue engineering | Q44185258 |
| | Electrospinning of poly(ethylene-co-vinyl alcohol) fibers. | Q44264123 |
| | Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein | Q44551921 |
| | Preparation and ectopic osteogenesis in vivo of scaffold based on mineralized recombinant human-like collagen loaded with synthetic BMP-2-derived peptide | Q45771355 |
| | The effect of mesoporous bioactive glass on the physiochemical, biological and drug-release properties of poly(DL-lactide-co-glycolide) films. | Q46128067 |
| | Porous nano-HA/collagen/PLLA scaffold containing chitosan microspheres for controlled delivery of synthetic peptide derived from BMP-2. | Q46187566 |
| | Delivery of osteoinductive growth factors from degradable PEG hydrogels influences osteoblast differentiation and mineralization | Q46287978 |
| | Comparative study of osteogenic potential of a composite scaffold incorporating either endogenous bone morphogenetic protein-2 or exogenous phytomolecule icaritin: an in vitro efficacy study | Q46291073 |
| | A comparative study of mesoporous glass/silk and non-mesoporous glass/silk scaffolds: physiochemistry and in vivo osteogenesis. | Q46294986 |
| | Repair of a proximal femoral bone defect in dogs using a porous surfaced prosthesis in combination with recombinant BMP-2 and a synthetic polymer carrier | Q46604418 |
| | Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients | Q46954545 |
| | Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery. | Q47875657 |
| | In vitro and in vivo degradation of mineralized collagen-based composite scaffold: nanohydroxyapatite/collagen/poly(L-lactide). | Q47978346 |
| | A mesoporous bioactive glass/polycaprolactone composite scaffold and its bioactivity behavior. | Q50967147 |
| | Three-dimensional fibrous PLGA/HAp composite scaffold for BMP-2 delivery. | Q50979277 |
| | Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(L-lactic-co-glycolic acid) scaffold. | Q51051801 |
| | Chemical characteristics and cytocompatibility of collagen-based scaffold reinforced by chitin fibers for bone tissue engineering. | Q51331617 |
| | Enhanced osteoinduction by controlled release of bone morphogenetic protein-2 from biodegradable sponge composed of gelatin and beta-tricalcium phosphate. | Q51530071 |
| | Temporal and spatial expression of bone morphogenetic protein-2, -4, and -7 during distraction osteogenesis in rabbits | Q74234116 |
| | Evaluation of recombinant human bone morphogenetic protein-2 in oral applications including the use of endosseous implants: 3-year results of a pilot study in humans | Q74266519 |
| | Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages | Q78412809 |
| | Bone morphogenetic proteins in musculoskeletal medicine | Q82551202 |
| | Segmental bone regeneration using rhBMP-2-loaded collagen/chitosan microspheres composite scaffold in a rabbit model | Q83497500 |
| | Repair of rat cranial bone defects with nHAC/PLLA and BMP-2-related peptide or rhBMP-2 | Q83888562 |
| | Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures | Q84147862 |
| | Pivotal, randomized, parallel evaluation of recombinant human bone morphogenetic protein-2/absorbable collagen sponge and autogenous bone graft for maxillary sinus floor augmentation | Q84419210 |
| | Enhanced osteoblastic activity and bone regeneration using surface-modified porous bioactive glass scaffolds | Q84701351 |
| P433 | issue | 3 | |
| P921 | main subject | drug delivery | Q1392806 |
| | tissue engineering | Q1540285 |
| P304 | page(s) | 155-161 | |
| P577 | publication date | 2013-09-01 | |
| P1433 | published in | Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases | Q26842318 |
| P1476 | title | Drug delivery using composite scaffolds in the context of bone tissue engineering | |
| P478 | volume | 10 | |